Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04545359
Other study ID # RCB 2017-A02786-47
Secondary ID 17001
Status Recruiting
Phase N/A
First received
Last updated
Start date December 12, 2018
Est. completion date September 15, 2021

Study information

Verified date September 2020
Source Centre National de la Recherche Scientifique, France
Contact Philippe Fossati, Pr
Phone +33 1 42 16 28 70
Email philippe.fossati@psl.aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This longitudinal study deals with the characterization of the electrophysiological and behavioral effects of alpha-based neurofeedback training on the brain networks involved in the relaxation process of healthy people.


Description:

Despite a growing number of studies dedicated to neurofeedback, the underlying cerebral mechanisms (plasticity phenomena underlying neurofeedback training or learning) are very poorly known. In most of the work on stress and anxiety reduction, the neural parameters on which neurofeedback is performed are low frequency waves like alpha waves. But the effects that an alpha-based neurofeedback has on these waves and more generally on the oscillatory behaviour of the networks involved after the neurofeedback sessions, are very little studied.

Thus, the NEURORELAX study aims to clarify the effects on neurofeedback training at the (electro)physiological level (changes in brain responses in terms of frequency of oscillations, power and location of the cerebral sources of these activities) and/or behavioural level (relaxation and reduced susceptibility to anxiety). It will use the Melomind neurofeedback device as built by myBrain Technologies company, which will make it additionally possible to assess feasibility of neurofeedback training with this reduced mobile device comprising of 2 dry electrodes. For these purposes, the investigators will propose a series of auditory neurofeedback training sessions to the participants, accompanied by electrophysiological (EEG) and clinical measures. The level of relaxation of the subjects will be characterized by self-reported questionnaires and by electrophysiological signal measurement.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 15, 2021
Est. primary completion date September 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Voluntary adult subjects, aged 18 to 60

- No known neurological history

- Having an anxiety level higher than 35 on the STAI-YA scale

- Insured under the French social security system

- Signature of the informed consent

- Absence of visual, hearing, sensory or motor deficits incompatible with participation in the study

Exclusion Criteria:

- recreational use of psychotropic drugs

- ongoing anxiolytic / benzodiazepine treatment

- current depressive episode and/or generalized anxiety troubles

- person under guardianship, curatorship or safeguarding of justice or any other measure

- administrative or judicial deprivation of rights or liberty

- pregnant or breastfeeding

- unable to give consent

- person subject to a period of exclusion from further research

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Alpha-based neurofeedback
Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions. Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.
Sham neurofeedback
Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions. Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.

Locations

Country Name City State
France Centre de Neuro-Imagerie de recherche (CENIR), ICM Paris

Sponsors (5)

Lead Sponsor Collaborator
Centre National de la Recherche Scientifique, France Institut du Cerveau et de la Moelle Epinière, Institut National de la Santé Et de la Recherche Médicale, France, myBrain Technologies, Sorbonne University

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in alpha frequency band power at the end of the 12 neurofeedback training sessions relative to the initial, pre-training, alpha power level. Individual EEG power measures in alpha band (between 7 and 13 Hz), performed over several minutes at rest, pre- and post-training, on every session. From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.
Primary Change in alpha frequency band power at post-training relative to pre-training across every training session. Individual EEG power measures in alpha band (between 7 and 13 Hz), performed over several minutes at rest, pre- and post-training, on every session. From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.
Secondary Change in the EEG power spectrum at the end of the 12 neurofeedback training sessions relative to the initial, pre-training, EEG spectral content. EEG signal measurement performed over several minutes at rest, pre- and post-training, on every session; EEG power spectrum analysis between 0.5 and 45 Hz. From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.
Secondary Change in the EEG power spectrum at post-training relative to pre-training across every training session. EEG signal measurement performed over several minutes at rest, pre- and post-training, on every session; EEG power spectrum analysis between 0.5 and 45 Hz. From the 1st training session until the end of the 12th training session, the time frame of the assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.
Secondary Change in anxiety trait after the 12 neurofeedback training sessions relative to before the first training session. Anxiety trait level measured by the State-Trait Anxiety Inventory (Trait evaluation, STAI-YA), before the 1st neurofeedback training session and after the last neurofeedback training session. Assessments are performed before the 1st training session (at day 1) and after the 12th training session (at day 22 up to 96, depending on the number of training sessions per week (1 minimum, 3 maximum)).
Secondary Change in affective state after the 12 neurofeedback training sessions relative to before the first training session. Affective state measured by the Positive and Negative Affect Schedule (PANAS), before the 1st neurofeedback training session and after the last neurofeedback training session. Assessments are performed before the 1st training session (at day 1) and after the 12th training session (at day 22 up to 96, depending on the number of training sessions per week (1 minimum, 3 maximum)).
Secondary Change in stress level after the 12 neurofeedback training sessions relative to before the first training session. Subjective stress level measured by the Perceived Stress Scale (PSS), before the 1st neurofeedback training session and after the last neurofeedback training session. Assessments are performed before the 1st training session (at day 1) and after the 12th training session (at day 22 up to 96, depending on the number of training sessions per week (1 minimum, 3 maximum)).
Secondary Changes in anxiety state at post-training relative to pre-training across every training session. Anxiety state level measured by the State-Trait Anxiety Inventory (State evaluation, STAI-YB) before and after every training session. Assessments are performed before and after every training session; the estimated period of time of assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.
Secondary Change in relaxation state at post-training relative to pre-training across every training session. Subjective relaxation state measured by a visual analog scale before and after every training session. Assessments are performed before and after every training session; the estimated period of time of assessment is 22 days minimum and 96 days maximum, with a minimum of 1 training session and a maximum of 3 training sessions per week.
Secondary Correlation between the changes in electrophysiological measurements and the changes in behavioral measures. Correlation between EEG power spectrum features and scores at behavioral questionnaires and scales, across training sessions. From the 1st training session until the 12th training session (minimum of 22 days and maximum of 96 days, with a minimum of 1 training session and a maximum of 3 training sessions per week).
Secondary Changes in EEG power spectrum during the training sessions from the 1st until the 12th sessions. EEG signal measured continuously during the 21 minutes of neurofeedback training, on every session; EEG power spectrum analysis between 0.5 and 45 Hz. From the 1st training session until the 12th training session (minimum of 22 days and maximum of 96 days, with a minimum of 1 training session and a maximum of 3 training sessions per week).
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Not yet recruiting NCT00966784 - The Effect of 2 Months Daily Supplementation of Orange Juice With Fibers Phase 1/Phase 2
Not yet recruiting NCT00966862 - The Glycemic Effect of Taking a Supplementation of Orange Juice With Fibers Phase 1/Phase 2
Recruiting NCT04213105 - Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults Phase 1
Completed NCT01840982 - The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male N/A
Not yet recruiting NCT05619393 - Comparison of Kinematic Movements Between ACL Deficiency With ACL Reconstruction and Healthy People N/A
Recruiting NCT05095753 - Data Collection of Heart Rate and Blood Pressure
Enrolling by invitation NCT05140577 - Reliability and Validity of the Evaluation of Hip Abductors Strength (RAVEHABDS)
Completed NCT05888246 - Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram N/A
Not yet recruiting NCT04319211 - Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress
Recruiting NCT01261195 - Establishment of Vascular Permeability Model for Research Purpose by Human Umbilical Vascular Endothelial Cells N/A
Not yet recruiting NCT01079585 - The Effect of 40gr Okara on Gastric Emptying N/A
Completed NCT01476865 - Articular Sonography: Healthy Subjects Versus Rheumatoid Arthritis Patients N/A
Not yet recruiting NCT01075568 - The Satiety Effect After Okara Compared to Porridge Eating N/A
Completed NCT04389255 - Developing a Balance Assessment System
Not yet recruiting NCT06303635 - Safety of UFRJvac, Trivalent COVID-19 Vaccine
Recruiting NCT03293056 - HIIH Versus HMC: Randomized Clinical Trial N/A
Not yet recruiting NCT06186635 - Comparison of Traditional and Artificial Intelligence-Assisted Yoga N/A
Not yet recruiting NCT06006182 - The Effects of Freeze-Dried Whole Grape Powder on Chronic Disease and Cardiovascular Risk Factors-a Pilot Study N/A
Completed NCT03651947 - Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults Phase 1